Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies

The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

Venous Thrombosis III: Interprofessional Care

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Venous Thrombosis I: Introduction

Venous Thrombosis I: Introduction

Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Non-linear association of coagulation factor XI with mortality.

Med (New York, N.Y.)·2025

Same author

Blood coagulation in Prediabetes clusters-impact on all-cause mortality in individuals undergoing coronary angiography.

Cardiovascular diabetology·2024

Same author

Clinical practice, research, and collaboration with industry: impact of the discontinuation of a critical device.

British journal of anaesthesia·2024

Same author

Gender-Associated Variation in DOAC Levels.

Clinical laboratory·2023

Same author

Platelet Reactivity and Cardiovascular Mortality Risk in the LURIC Study.

Journal of clinical medicine·2023

Same author

Judging Urgency in 343 Ectopic Pregnancies Prior to Surgery - The Importance of Transvaginal Sonographic Diagnosis of Intraabdominal Free Blood.

Ultraschall in der Medizin (Stuttgart, Germany : 1980)·2023

Same journal

Profilin-1 as a Potential Biomarker in Acute Ischemic Stroke: Predictive Value for Large Vessel Occlusion and Mechanical Thrombectomy.

Clinical laboratory·2026

Same journal

Soluble Thrombomodulin can Predict In-Hospital Mortality of Community-Acquired Pneumonia Patients in Intensive Care Unit.

Clinical laboratory·2026

Same journal

Cytomegalovirus Seroprevalence in Morocco - a 10-Year Single-Center Study.

Clinical laboratory·2026

Same journal

Impact of Inactivated SARS-CoV-2 Vaccines on Serum Glycan Profiles and Protein N-Glycosylation.

Clinical laboratory·2026

Same journal

Albumin Concentration Associates Linearly with Unfavorable Outcomes at Three Months Post-Acute Ischemic Stroke in Koreans.

Clinical laboratory·2026

Same journal

Prognostic Value of the Blood Urea Nitrogen-to-Albumin Ratio for ICU Mortality in Cardiogenic Shock Patients: Evidence from the MIMIC-IV Database.

Clinical laboratory·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Aug 2, 2025

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Thrombophilia Testing - a Systematic Review.

Lars Asmis, Peter Hellstern

Clinical Laboratory

|April 14, 2023

Summary

This summary is machine-generated.

Thrombophilia testing aids in risk stratification for venous thromboembolism (VTE). Accurate interpretation of thrombophilia tests, considering clinical factors, guides treatment decisions for anticoagulation and hormone therapy.

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Related Experiment Videos

Last Updated: Aug 2, 2025

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

In Vitro Thrombosis Test for Ventricular Assist Devices

In Vitro Thrombosis Test for Ventricular Assist Devices

Published on: March 21, 2025

Area of Science:

Hematology
Genetics
Reproductive Medicine

Background:

Thrombophilia testing is costly and complex, often limited by remote laboratory capabilities.
Previous testing guidelines were based on incomplete data and simplified risk assessments for venous thromboembolism (VTE).

Conclusions:

Thrombophilia testing is indicated when results impact treatment type and duration, particularly for VTE risk.
Testing informs decisions regarding anticoagulation, hormonal contraception, and hormone replacement therapy.
Risk stratification using thrombophilia markers and clinical factors guides therapeutic strategies.